Download PDF

1. Company Snapshot

1.a. Company Description

bioAffinity Technologies, Inc., a biotechnology company, engages in developing non-invasive diagnostic tests and targeted cancer therapeutics.The company offers CyPath lung, a diagnostic test, for early detection of lung cancer.It also researches targeted therapies to treat cancer at the cellular level.


The company was founded in 2014 and is based in San Antonio, Texas.

Show Full description

1.b. Last Insights on BIAF

bioAffinity Technologies' recent performance was negatively driven by the company's decision to cut $4 million in costs, implying potential restructuring and layoffs. This move may indicate declining revenue or inefficient operations. Additionally, the company's warrant inducement transactions raised $1.4 million in gross proceeds, which may have been necessary due to cash flow constraints. These developments suggest that bioAffinity is navigating challenging market conditions and may be making adjustments to mitigate financial pressures.

1.c. Company Highlights

2. Transcript Summary

Unfortunately this company is not part of our coverage yet. But as part of your subscription plan you can request it by clicking just below and we'll process.

Request Coverage

3. NewsRoom

Card image cap

New Case Study Highlights Ability of bioAffinity Technologies' CyPath® Lung to Reduce Diagnostic Burden for Patients At Risk for Lung Cancer

Feb -19

Source: businesswire.com

Card image cap

Clinical Utility of bioAffinity Technologies' CyPath® Lung Test Demonstrated in Real-World Case Study

Feb -17

Source: businesswire.com

Card image cap

bioAffinity Technologies Appoints Nationally Recognized Pulmonary and Lung Cancer Authorities to its Medical and Scientific Advisory Board

Feb -09

Source: businesswire.com

Card image cap

bioAffinity Technologies' Laboratory Maintains Prestigious College of American Pathologists (CAP) Accreditation

Jan -07

Source: businesswire.com

Card image cap

bioAffinity Technologies, Inc. (NASDAQ:BIAF) Short Interest Down 43.3% in December

Dec -27

Source: defenseworld.net

Card image cap

bioAffinity Technologies (NASDAQ:BIAF) Stock Price Down 4.9% – Here’s What Happened

Dec -27

Source: defenseworld.net

Card image cap

Reviewing bioAffinity Technologies (NASDAQ:BIAF) and Briacell Therap (NASDAQ:BCTX)

Dec -07

Source: defenseworld.net

Card image cap

bioAffinity Technologies' Noninvasive CyPath® Lung Test to Be Highlighted at American Cancer Society National Lung Cancer Roundtable

Dec -03

Source: businesswire.com

4. Business Breakdown

4.a. Revenues by Country

4.b. Revenues by Segment

5. Expected revenues mid-term growth (10.47%)

6. Segments

Laboratory Services

Expected Growth: 10.47%

bioAffinity Technologies, Inc.'s Laboratory Services segment growth of 10.47% is driven by increasing demand for non-invasive diagnostic tests, expansion into new markets, and strategic partnerships. Additionally, advancements in cancer diagnostics and growing adoption of precision medicine are contributing to the segment's growth.

Diagnostic Research and Development

Expected Growth: 10.45%

BioAffinity Technologies' Diagnostic Research and Development segment growth of 10.45% is driven by increasing demand for non-invasive cancer diagnostics, advancements in proprietary CyPath technology, and strategic partnerships expanding its customer base. Additionally, growing investments in R&D and expanding product offerings are contributing to the segment's rapid growth.

7. Detailed Products

CyPath Lung

A non-invasive, early-stage lung cancer diagnosis test that uses proprietary technology to detect cancer cells in sputum samples.

CyPath Lung Complete

A comprehensive lung cancer diagnosis test that combines CyPath Lung with additional biomarkers to provide a more accurate diagnosis.

CyPath Research

A research-use-only version of CyPath Lung, designed for researchers and clinicians to study lung cancer and develop new biomarkers.

8. bioAffinity Technologies, Inc.'s Porter Forces

Forces Ranking

Threat Of Substitutes

bioAffinity Technologies, Inc. operates in a niche market with limited substitutes, but the threat of substitutes is still present due to the evolving nature of the biotechnology industry.

Bargaining Power Of Customers

bioAffinity Technologies, Inc. has a diverse customer base, which reduces the bargaining power of individual customers. Additionally, the company's products are highly specialized, making it difficult for customers to switch to alternative suppliers.

Bargaining Power Of Suppliers

bioAffinity Technologies, Inc. relies on a few key suppliers for critical components, which gives these suppliers some bargaining power. However, the company's strong relationships with its suppliers and its ability to negotiate favorable terms mitigate this risk.

Threat Of New Entrants

The biotechnology industry has high barriers to entry, including significant capital requirements and regulatory hurdles. This makes it difficult for new entrants to compete with established companies like bioAffinity Technologies, Inc.

Intensity Of Rivalry

The biotechnology industry is highly competitive, with many established players competing for market share. bioAffinity Technologies, Inc. must continually innovate and improve its products to maintain its competitive edge.

9. SWOT Analysis

Strength

Weaknesses

Opportunities

Threats

10. Capital Structure

10.a. Balance Sheet

10.b. Weighted Average Cost of capital

Value
Debt Weight 24.54%
Debt Cost 3.95%
Equity Weight 75.46%
Equity Cost 23.90%
WACC 19.01%
Leverage 32.51%

11. Quality Control: bioAffinity Technologies, Inc. passed 3 out of 9 key points

12.a Historical Valuation

12.b Price/Earnings Ratio

12.c Margin Valuation

12.d Peers Valuation

Peers Group Analysis

Stock-Card
DermTech

A-Score: 3.8/10

Value: 10.0

Growth: 3.3

Quality: 2.8

Yield: 0.0

Momentum: 6.0

Volatility: 0.3

1-Year Total Return ->

View Full Report
Stock-Card
Bionano Genomics

A-Score: 3.3/10

Value: 10.0

Growth: 4.3

Quality: 4.0

Yield: 0.0

Momentum: 0.5

Volatility: 1.0

1-Year Total Return ->

View Full Report
Stock-Card
T2 Biosystems

A-Score: 3.2/10

Value: 10.0

Growth: 4.7

Quality: 4.8

Yield: 0.0

Momentum: 0.0

Volatility: 0.0

1-Year Total Return ->

View Full Report
Stock-Card
Aclaris Therapeutics

A-Score: 3.2/10

Value: 6.7

Growth: 6.7

Quality: 4.0

Yield: 0.0

Momentum: 0.5

Volatility: 1.3

1-Year Total Return ->

View Full Report
Stock-Card
bioAffinity Technologies

A-Score: 3.1/10

Value: 9.6

Growth: 4.6

Quality: 4.0

Yield: 0.0

Momentum: 0.5

Volatility: 0.0

1-Year Total Return ->

View Full Report
Stock-Card
Inotiv

A-Score: 2.8/10

Value: 9.0

Growth: 3.1

Quality: 2.1

Yield: 0.0

Momentum: 2.0

Volatility: 0.3

1-Year Total Return ->

View Full Report

Peers Metrics

12.e Scoring Insights

12.f DCF BETA

Parameters

Short Term Growth

Short term Time

Long-Term Growth

WACC

Target Price

1.08$

Current Price

1.08$

Potential

-0.00%

Expected Cash-Flows